Kornimate/medical-research-clean huggingface dataset:
prognostic significance of cmr-confirmed infarct in minoca patients from sweden and australia

Conditions: MINOCA

Summary: myocardial infarction (mi) with non-obstructive coronary arteries (minoca), occurring in 6-8% of mis, refers to patients who experience a heart attack without obstructive coronary artery disease (cad) or significant atherosclerosis. one of the challenges inherent to minoca lies in its propensity to mimic non-coronary-related pathologies, such as myocarditis or takotsubo. thus, cardiac magnetic resonance (mri) imaging has been recommended as the central diagnostic tool for confirming minoca diagnosis while excluding the others. however, the resource-intensive nature of mri, combined with its limited availability in hospitals, poses barriers to patient access and limits research activities that could produce significant impact. therefore, this project's aim is to curate the largest dataset of suspected minoca patients with mri, via a collaboration between sweden's nationwide registry and south australia's state-wide registry, to answer the following key questions: (i) what is prognosis of minoca, as confirmed by mri? (ii) what are the characteristics and prognosis of patients who had mri compared to those who did not? (iii) what clinical parameters are associated with minoca on mri? this project will utilize datashield, an innovative platform that enables pooled statistical analysis of sensitive data without compromising individual-level privacy. this multicentre, comprehensive study will have a major impact on contemporary practice. it will be able to provide the significance of minoca diagnosis (myocardial scar on mri), alongside identifying clinical factors associated with its occurrence and its correlation with long-term outcomes. this is crucial for informing clinical guidelines, policy decisions around reimbursement for mri, and developing effective clinical trials to enhance the management of mri-confirmed minoca patients


Eligibility criteria:
inclusion criteria: 1. discharge diagnosis of minoca - acute presentation with (a) universal criteria for acute mi (b) non-obstructive coronaries on angiography. 2. cardiac mri - at least within 3 months of acute presentation exclusion criteria: 1. patients without satisfactory images on cardiac mri 2. follow-up data not available (ie international visitors). 3. suspicion of an alternative cause for presentation (such as sepsis, pulmonary embolus, primary cardiac arrhythmia or trauma) which would not be consistent with the label of minoca. 4. clinically evident non-ischemic diagnoses - myocarditis, takotsubo, other cardiomyopathies prior to cmr

Keywords: cardiac magnetic resonance imaging prognosis myocarditis
pilot study of immediate hiv treatment in guangxi, china

Conditions: HIV; Acquired Immunodeficiency Syndrome

Summary: the aim of the study is to measure the effectiveness of a pilot program in guangxi, china to decrease mortality related to hiv. the study's proposed mechanism of decreasing mortality rates is to shorten the time between initial hiv screening and art implementation to within two weeks. the study population consists of participants who received an initial hiv infection diagnosis within the study period. medical institutions will provide "one-stop services" by following detailed guidelines regarding reporting of positive hiv antibody screenings, further testing procedures, and treatment referrals in accordance with a pre-determined timetable. in addition, additional strategies focusing on policy development, medical personnel training, and a broad general public education campaign will be implemented. main assessment measures are hiv-related mortality rates, treatment coverage, or other health outcomes.

the aim of the study is to measure the effectiveness of a pilot program in guangxi, china to decrease mortality related to hiv/aids. in past years, guangxi has experienced a relatively high rate of late hiv diagnoses, which has contributed to a significant proportion of hiv-related deaths occurring in the same year of initial diagnosis. the study's proposed mechanism of decreasing mortality rates is to shorten the time between initial hiv screening and art implementation to within two weeks. two pilot sites were selected based on past core assessment indicators. the study population consists of participants who received an initial hiv infection diagnosis within the study period. medical institutions will provide "one-stop services" by following detailed guidelines regarding reporting of positive hiv antibody screenings, further testing procedures, and treatment referrals in accordance with a pre-determined timetable. in addition, additional strategies focusing on policy development, medical personnel training, and a broad general public education campaign will be implemented. the study will be performed from july,2012 to july,2015. main assessment measures are hiv-related mortality rates, treatment coverage, or other health outcomes. 1. hiv-related mortality rates of participants who are newly diagnosed during the study period numerator: number of all-cause deaths during the study period denominator: number of hiv infected patients followed during the study period. 2. percentage of newly diagnosed hiv-infected participants who receive art numerator: number of patients who are diagnosed with hiv and initiate art during the study period denominator: number of newly reported hiv cases during the study period

Eligibility criteria:
inclusion criteria: * new diagnosis of hiv infection as defined by having positive hiv antibody screening results between july 1, 2012 and july 1, 2015 or * having a current residential address inside of pilot site limits exclusion criteria: * current residing outside of the borders of the designated study sites

Keywords: antiretroviral therapy education mortality
lenalidomide monotherapy in r/r dlbcl

Conditions: Diffuse Large B Cell Lymphoma

Summary: this observational study is designed to characterise the effectiveness of lenalidomide monotherapy in the treatment of r/r dlbcl and to compare the results with the efficacy outcomes of a tafasitamab-lenalidomide combination therapy in the clinical trial mor208c203 (l-mind)

tafasitamab (mor00208) is currently in development for the treatment of r/r dlbcl. an ongoing, single-arm, phase ii, open label, multicenter study (mor208c203) is evaluating the efficacy and safety of tafasitamab combined with lenalidomide in patients with r/r dlbcl. in order to establish a lenalidomide monotherapy as a control cohort, this observational study aims to collect retrospective lenalidomide monotherapy data from real-world-evidence and to compare it with the tafasitamab-lenalidomide combination therapy.

Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of dlbcl * relapsed/refractory to at least one previous systemic therapy for dlbcl * received at least one, but no more than three previous systemic regimens for the treatment of dlbcl, including at least one anti-cd20 containing therapy * received lenalidomide monotherapy for r/r dlbcl while being considered not eligible for an asct exclusion criteria: * cns involvement by lymphoma * patients who received lenalidomide in combination with another anti-lymphoma therapy (including radiation) * previously treated with anti-cd19-targeted therapy or immunomodulatory drugs * patients who previously underwent allogeneic sct * known simultaneous detection of myc and bcl2 or bcl6 translocation according to fish * patients with a history of other malignancies within 5 years prior to lenalidomide treatment start
a study of biochemical response to alternative proteins

Conditions: Postprandial Hyperglycemia; Overweight and Obesity; Type2diabetes

Summary: the overall objective of this research is to determine the digestive faith and health impact of protein and fiber rich foods in different food matrices in type 2 diabetes risk population. this is achieved by controlled postprandial intervention where plasma amino acids, lipids, glucose metabolism, bile acids and microbial metabolites are evaluated as well as fecal microbiota and metabolites.

detailed research aim of this controlled, randomized crossover postprandial clinical study are: 1. to study the impact of complex plant- and animal-based foods on glucose metabolism, acute inflammation, and markers of microbial fermentation of fiber and proteins. 2. to investigate the difference in the gut mediated metabolism induced by naturally occurring fiber fraction bound plant protein or by plant protein with added fiber when compared to animal protein. 3. to conduct in vitro experiments using fecal samples from participants in the meal study to investigate the distinctions between different animal and plant proteins on both host and microbial metabolites, as well as the function of the gut barrier.

Eligibility criteria:
inclusion criteria: * 30-65 years of age * bmi \>25 kg/m2 and \<35 kg/m2 * waist circumference with females \>85 cm and with males \>100 cm exclusion criteria: * certain chronic diseases requiring regular medication (e.g., type 2 diabetes, chronic liver, kidney, thyroid, or gastrointestinal diseases) * pregnancy or breastfeeding * gluten-free or vegan diet * use of antibiotics within the last 12 months * gastrointestinal surgery within the last two years * high alcohol consumption
investigate beneficial effect of herbal tea in jordanian adults

Conditions: Diet, Healthy

Summary: investigate beneficial effect of an herbal tea prepared from carob pulp and pods (ceratonia siliqua), anise seed (pimpinella anisum l), wild thyme, green tea and eucalyptus leaves with manuka honey (natural sweetener) on lipid profile and insulin resistance, crp (c-reactive protein), cbc (complete blood count), liver function test, kidney function tests, inflammation and anthropometric indices in adults living in amman jordan

this study will be carried out to examine the effect of herbal tea in recruited subjects in an intervention single-group pretest-posttest study for a period of 7 weeks. subjects will consume twice a day for a period of 7 weeks an herbal tea of (carob, anise, wild thyme, and eucalyptus leaves) before eating. the total sample (n=30) adults aged (19-57 years) , body mass index bmi range (19-35 kg/m2)

Eligibility criteria:
inclusion criteria: * adults aged 19-57 years * male to female ratio (1:1 ratio) * bmi 19-35 kg/m2 * currently living in amman * without significant apparent diseases * able to drink the tested herbal tea twice a day exclusion criteria: * have chronic diseases such as diabetes, hypertension, cardiovascular or endocrine diseases or disabilities * using medical drugs and/or supplements * below 19 or above 57 years. * participation in clinical trials within the last 2 months * use of lipid-lowering drugs, or diabetic medication. * lactating and pregnant women will be also excluded.

Keywords: herbal tea infusion carob green tea anise insulin resistance inflammation health lipid profile manuka honey
ovarian hyperstimulation syndrome using calcium infusion

Conditions: Ovarian Hyperstimulation Syndrome

Summary: the incidence of ohss and clinical outcomes after calcium iv infusion in high-risk women undergoing art

among assisted reproductive technologies (art), ovarian hyperstimulation syndrome (ohss) is a serious iatrogenic complication affects up to 30% of women undergoing art and caries high risks of morbidity and mortality. women with age younger than 35 years, those with history of polycystic ovary syndrome (pcos), or having a history of previous ohss are more susceptible to develop ohss

Eligibility criteria:
inclusion criteria: - infertile women aged 20 to 38 years. bmi ranged from 18 to 40. serum fsh within normal limits( 1-12iu /l) presented with ovarian response suggestive of being at risk of developing ohss because of the presence of at least 15 follicles of 10 mm or greater on the day of hcg administration. exclusion criteria: * endocrinopathies. a systemic disease. and insulin-dependent diabetes thyroid disease using any medication (e.g., insulin-sensitizing drugs and gnrh antagonists. patients need coasting for high risk of ohss. patients need cycle cancellation. severe male infertility requiring testicular sperm extraction.

Keywords: ohss calcium infusion ivf icsi
a validation study to determine concordance of liquid biopsy and breast cancer diagnosis

Conditions: Breast Carcinoma

Summary: this study evaluates whether a special type of blood analysis, called liquid biopsy (lbx), correlates with mammography results and/or diagnosis of breast cancer.

primary objectives: i. determine the sensitivity of lbx for the presence of breast cancer in patient cohorts ii. determine the specificity of lbx for the presence of breast cancer in all patient cohorts. outline: this is an observational study. patients undergo blood sample collection and have their medical records reviewed on study.

Eligibility criteria:
inclusion criteria: * \* women * age ≥ 18 years. * screening mammography cohort: patients who were referred for screening mammography and had mammography performed within 6 months prior to blood draw or will be undergoing mammography within 6 months after blood draw. patient must not have personal history of breast cancer, history of breast biopsy or prior abnormal mammography findings are allowed. or * abnormal screening cohort: patient who has had mammography that revealed abnormal results (birads 3, 4, 5) or abnormal mri results requiring further testing (additional imaging modality or biopsy). patients must not have a history of breast cancer, history of breast biopsy, or prior abnormal mammography findings are allowed. the blood draw must occur in the time between the abnormal mammography and start of definitive treatment (surgery or neoadjuvant chemotherapy). patients who have already undergone surgery/excisional biopsy due to abnormal mammography findings are not eligible. or * new beast cancer cohort: patients with new biopsy proven diagnosis of breast cancer (invasive breast cancer or dcis) within 60 days of blood draw who has not started any cancer directed therapy, including surgery, radiation, hormonal therapy or chemotherapy. any breast cancer type patients at any stage are eligible. or * remission breast cancer cohort: patients with personal history of localized breast cancer (stage 1, 2, 3) that has been previously treated with cancer directed therapy, such as surgery, chemotherapy, radiation and/or hormonal therapy who has been in completed remission. patients must complete their surgery, adjuvant chemotherapy and/or radiation therapy prior to enrollment. the blood draw must occur at least 90 days after completion of the specified treatment modalities. patients on adjuvant hormonal therapy are eligible to enroll (those who are treated with adjuvant hormonal therapy in combination with cdk4/6 inhibitor must complete cdk4/6 inhibitor therapy prior to enrollment). exclusion criteria: * \* patients unable to give informed consent * patients who have received blood transfusion with 14 days prior to study blood draw * patients who had a heart attack, stroke, or pulmonary embolism within 3 months to study blood draw * excisional breast biopsy in the prior 30 days. needle biopsy of the breast is permitted

Keywords: liquid biopsy
study for azd4360 in participants with advanced solid tumours

Conditions: Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarcinoma

Summary: the purpose of this study is to evaluate the safety, tolerability, pk, immunogenicity, pharmacodynamics, and preliminary efficacy of azd4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of cldn18.2.


Eligibility criteria:
inclusion criteria: 1. participant must be ≥ 18 at the time of signing the icf. 2. eastern cooperative oncology group performance status of 0-1 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing. 3. minimum life expectancy of 12 weeks in the opinion of the investigator. 4 adequate organ and marrow function, as defined by protocol. 5. contraceptive use by men or women should be consistent with local regulations, as defined by protocol. 6. histologically confirmed advanced or metastatic pancreatic ductal adenocarcinoma (pdac), gastric or gastroesophageal junction cancer (g/gejc), and biliary tract cancer (btc) with documented positive cldn18.2 expression. 7. participants must have received at least one prior line of systemic therapy in the advanced/metastatic disease. 8. at least one measurable lesion according to recist v1.1. exclusion criteria: 1. human epidermal growth factor receptor 2 (her2) positive (3+ by ihc or 2+ by ihc and positive by in situ hybridisation) or indeterminate g/gejc participants. 2. unstable or active peptic ulcer disease or digestive tract bleeding including but not limited to clinically significant bleeding in the setting of prior cldn18.2 directed therapy. 3. participants with clinically significant ascites that require drainage. 4. central nervous system (cns) metastases or cns pathology, as defined by protocol. 5. with spinal cord compression or with high risk of paralysis. 6. history of non-infectious interstitial lung disease/pneumonitis. 7. participant has cardiac abnormalities, as defined by protocol. 8. history of another primary malignancy within 2 years prior to screening. 9. known serologic status reflecting active hepatitis b or hepatitis c. 10. known hiv infection that is not well controlled. 11. active tuberculosis infection.

Keywords: gastric cancer gastroesophageal junction cancer biliary tract cancer pancreatic ductal adenocarcinoma advanced solid tumours azd4360 claudin 18.2
stimulation to improve auditory hallucinations

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: investigating the effects of non-invasive transcranial current stimulation as a treatment for auditory hallucinations in patients with schizophrenia.

the investigator's primary objective is to conduct a pilot clinical trial to establish the feasibility and to collect first effectiveness data for the use of transcranial alternating current stimulation (tacs) to re-normalize pathological alpha oscillations in dorso-lateral prefrontal cortex (dl-pfc) of patients with schizophrenia or schizoaffective disorder by comparing auditory hallucination rating scale (ahrs) scores immediately before the first stimulation session and immediately after the last stimulation session. as a secondary objective the investigators will assess the differential clinical effects of sham, 10 hz and 2 ma transcranial direct current stimulation (tdcs) on electroencephalogram (eeg) measures of alpha oscillations.

Eligibility criteria:
inclusion criteria: * dsm-iv diagnosis of schizophrenia, any subtype, or schizoaffective disorder, with refractory auditory hallucinations. duration of illness \>1 year * 18-70 years old * clinically stable for at least 12 weeks, i.e. not requiring hospitalization or a change in level of care * on current antipsychotic doses for at least 4 weeks * stable auditory hallucinations as demonstrated by having less than or equal to 20% change in ahrs scores across a 2 week interval during the screening period. * capacity to understand all relevant risks and potential benefits of the study and to provide written informed consent, or has a legal guardian who can provide informed consent on the patient's behalf with the patient providing written assent to participate. exclusion criteria: * dsm-iv diagnosis of alcohol of substance abuse (other than nicotine) within the last month or a dsm-iv diagnosis of alcohol or substance dependence (other than nicotine) within the last 6 months * medical or neurological illness (unstable cardiac disease, aids, malignancy, liver or renal impairment) or treatment for a medical disorder that could interfere with study participation * history of traumatic brain injury that required subsequent cognitive rehabilitation, or caused cognitive sequelae * prior brain surgery * any brain devices/implants, including cochlear implants and aneurysm clips * co-morbid neurological condition (e.g. seizure disorder, brain tumor) * non english speakers * female participants who are pregnant, nursing, or unwilling to use an adequate method of contraception during study participation for those of childbearing potential * positive urine test for cannabis, cocaine, amphetamine, barbiturates, benzodiazepines, opiates

Keywords: tacs tdcs sham auditory hallucinations schizophrenia schizoaffective disorder
a phase 2 study to investigate the clinical activity of ipi-504 in patients with hormone-resistant prostate cancer

Conditions: Prostate Cancer; Prostatic Neoplasms; Cancer of the Prostate

Summary: to determine: * anti-tumor activity of ipi-504 in 2 groups of subjects with hormone resistant prostate cancer. * group a - subjects who have not previously received chemotherapy * group b - sujects who have received prior chemotherapy or could not tolerate chemotherapy. * clinical response will be determined by psa and radiological response

ipi-504 is a novel, water-soluble analog of 17-aag and a potent inhibitor of hsp90. hsp90's role in the cell is to control the proper folding, function, and viability of various "client" proteins. many of these client proteins (such as akt, her-2, bcr-abl, pdgfr-α, and c-kit) are oncoproteins or important cell signaling proteins. inhibition of hsp-90 leads to the proteasomal degradation of these proteins. in patients with hrpc,there are several proteins that are important in the progression of hrpc, including ar, akt and her-2. all of these are client proteins of hsp90 and in response to hsp90 inhibition are degraded by their proteasome. preclinical studies have shown that hsp90 inhibition causes a dose dependent degradation of these client proteins and growth inhibition of prostate cancer in xenograft tumors.

Eligibility criteria:
inclusion criteria: * adenocarcinoma of the prostate * resolution of acute toxic side effects of prior chemotherapy * castration resistant disease despite ongoing chemical or surgical castration * ecog 0-1 * psa greater than or equal to 2 * group a - * no prior treatment for prostate cancer with cytotoxic chemotherapy (neoadjuvant, adjuvant treatment permitted if more than 2 years out) * group b * radiographic evidence of metastatic disease * prior tx with docetaxel-minimum of 2 cycles with progression by recist or psa or intolerant of tx * maximum of 3 prior chemotherapies exclusion criteria: * small cell carcinoma of the prostate * treatment within 2 weeks with approved, investigational, or small molecule * treatment within 4 weeks with biologic or external beam radiation * anc \<1,500 cells m3; platelets \<100,000 mm3; hemoglobin \<9.0g/dl * ast/alt \>2.5 uln * serum creatinine \>3.0mg/dl * active keratitis or keratoconjunctivitis * previous treatment with 17-aag, dmag; or any other hsp-90 inhibitor * baseline qtc \>450 mses

Keywords: hormone resistant prostate cancer castrate resistant prostate cancer hrpc crpc
the effectiveness of a patient self-reported pain scoring tool and a satisfaction survey on cancer pain management

Conditions: Pain

Summary: the purpose of this survey is to investigate the usefulness of a patient self-reported scoring tool on patient satisfaction improvement.


Eligibility criteria:
inclusion criteria: * patients who have no experience with the study self-reported pain scoring tool * patients who are able to understand and answer the pain scoring tool questions * patients admitted to a hospital for more than 5 days due to cancer pain * patients for whom their pain managing physicians completed the medical staff's survey exclusion criteria: * patients who cannot answer the questions due to cognitive impairments

Keywords: pain cancer pain self-reported pain scoring tool opioid analgesics